HPV particles and uses thereof
The invention relates to modified HPV particles that can be used therapeutically. Modified HPV particles may be used to deliver therapeutic agents, including siRNA molecules. Modified HPV particles may be used for the treatment of diseases or conditions of mucosal tissue, including HPV (human papilloma virus) infection and HPV-related tumors.
1. A nanoparticle comprising:
a papillomavirus L1 protein comprising an FG loop corresponding to the amino acid sequence of SEQ ID NO: 66, wherein the papillomavirus L1 protein has reduced immunogenicity relative to wild-type human papillomavirus (HPV) serotype 16.
2. The nanoparticle of claim 1 , wherein the nanoparticle comprises at least one heterologous compound.
3. The nanoparticle of claim 2 , wherein the at least one heterologous compound comprises at least one therapeutic agent.
4. The nanoparticle of claim 2 , wherein the at least one heterologous compound comprises at least one diagnostic agent.
5. The nanoparticle of claim 1 , wherein the nanoparticle is a self-assembled nanoparticle.
6. The nanoparticle of claim 1 further comprising papillomavirus L2 capsid protein.
7. A method of delivering to a subject the nanoparticle of claim 1 .
8. The method of claim 7 , wherein the nanoparticle comprises at least one heterologous compound.
9. The method of claim 8 , wherein the at least one heterologous compound comprises at least one therapeutic agent.
10. The method of claim 8 , wherein the at least one heterologous compound comprises at least one diagnostic agent.
11. The method of claim 7 , wherein the nanoparticle is a self-assembled nanoparticle.
12. A papillomavirus L1 protein comprising an FG loop corresponding to the amino acid sequence of SEQ ID NO: 66, wherein the papillomavirus L1 protein has reduced immunogenicity relative to wild-type human papillomavirus (HPV) serotype 16.